MedTrace Logo

Immunotherapy Before and After Surgery

NCT06765902 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2026-05-05

No results posted yet for this study

Summary

This Phase 2 clinical trial is testing a new immunotherapy combination (N-803, ETBX-071, M-CENK) for men with high-risk prostate cancer before and after prostate surgery. The goal is to see if this treatment improves cancer outcomes and is safe.

Conditions

  • High-risk Prostate Cancer

Interventions

DRUG

N-803

A subcutaneous injection of an IL-15 superagonist.

DRUG

ETBX-071

A subcutaneous injection of a prostate-specific antigen (PSA) adenovirus vaccine.

DRUG

M-CENK

An intravenous infusion of the patient's own NK cells that have been expanded and activated in a laboratory.

Sponsors & Collaborators

  • ImmunityBio, Inc.

    lead INDUSTRY

Principal Investigators

  • Bruce Brown · ImmunityBio, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-15
Primary Completion
2031-01-31
Completion
2031-06-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06765902 on ClinicalTrials.gov